EUVIMEDEUVIMED entdecken
Crossref

Polo‐like kinase 1 inhibition modulates urinary tract smooth muscle contraction and bladder cell transcriptional programs

Xiaolong Wang iD, Linfa Guo, Zuhaer Yisha, Aodun Gu, Tongzu Liu

Cytoskeleton · 2025

DOI: 10.1002/cm.21888 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytoskeleton, 2025. Verfasst von Xiaolong Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Cell Cycle Proteins, Proto-Oncogene Proteins, Urinary Bladder. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Li Huanying Foundation of Beijing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The serine/threonine kinase polo‐like kinase 1 (PLK1) is a master regulator of cell proliferation and contraction, but its physiological role in the lower urinary tract is unknown. We utilized transcriptomic programs of human bladder smooth muscle cells (hBSMCs), 3D bladder spheroid viability assays, and human ureterovesical junction contractility measurements to elucidate the impacts of PLK1 inhibition. This work reveals PLK1 reduction with the selective inhibitor TAK‐960 (500 nM) suppresses high K+‐evoked contractions of human urinary smooth muscle ex vivo while decreasing urothelial cell viability. Transcriptomic analysis of hBSMCs treated with TAK‐960 shows modulation of cell cycle and contraction pathways, specifically through altered expression of Cys2/His2‐type zinc finger transcription factors. In bladder spheroids, PLK1 inhibition also suppresses smooth muscle contraction protein filamin. Taken together, these findings establish PLK1 is a critical governor of urinary smooth muscle contraction and urothelial proliferation with implications for lower urinary tract disorders. Targeting PLK1 pharmacologically may therefore offer therapeutic potential to ameliorate hypercontractility and aberrant growth. Further elucidation of PLK1 signaling networks promises new insights into pathogenesis and much needed treatment advances for debilitating urinary symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesCell Cycle ProteinsProto-Oncogene ProteinsUrinary BladderMuscle ContractionMyocytes, Smooth MuscleMuscle, SmoothPolo-Like Kinase 1HumansCell Proliferation

Stichwörter der Autor:innen

contractionlower urinary tract symptomsoveractive bladderpolo‐like kinaseproliferation

Substanzen

Polo-Like Kinase 1Protein Serine-Threonine KinasesCell Cycle ProteinsProto-Oncogene Proteins

Autor:innen und Institutionen

  • Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Hubei Key Laboratory of Urological Diseases, Wuhan, China.
  • Hubei Clinical Research Center for Laparoscopic/Endoscopic Urologic Surgery, Wuhan, China.
  • Institute of Urology, Wuhan University, Wuhan, China.
  • Hubei Medical Quality Control Center for Laparoscopic/Endoscopic Urologic Surgery, Wuhan, China.
  • Wuhan Clinical Research Center for Urogenital Tumors, Wuhan, China.

ORCID-Profile: Xiaolong Wang

Förderung

  • Li Huanying Foundation of Beijing

Zitieren

APA

Wang, X., Guo, L., Yisha, Z., Gu, A., & Liu, T. (2025). Polo‐like kinase 1 inhibition modulates urinary tract smooth muscle contraction and bladder cell transcriptional programs. Cytoskeleton. https://doi.org/10.1002/cm.21888

Vancouver

Wang X, Guo L, Yisha Z, Gu A, Liu T. Polo‐like kinase 1 inhibition modulates urinary tract smooth muscle contraction and bladder cell transcriptional programs. Cytoskeleton. 2025. doi:10.1002/cm.21888

BibTeX
@article{Wang2025,
  author = {Wang, Xiaolong and Guo, Linfa and Yisha, Zuhaer and Gu, Aodun and Liu, Tongzu},
  title = {Polo‐like kinase 1 inhibition modulates urinary tract smooth muscle contraction and bladder cell transcriptional programs},
  journal = {Cytoskeleton},
  year = {2025},
  doi = {10.1002/cm.21888}
}
Kostenlos starten →